dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:36:51Z
dc.date.available2015-12-07T15:36:51Z
dc.date.created2015-12-07T15:36:51Z
dc.date.issued2015-08-11
dc.identifierInternational Ophthalmology, 2015.
dc.identifier1573-2630
dc.identifierhttp://hdl.handle.net/11449/131520
dc.identifier10.1007/s10792-015-0106-2
dc.identifier9420249100835492
dc.identifier8727897080522289
dc.identifier26260358
dc.identifier0000-0003-1515-702X
dc.description.abstractTo compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.
dc.languageeng
dc.publisherInternational Ophthalmology
dc.relationInternational Ophthalmology
dc.relation0,598
dc.rightsAcesso restrito
dc.sourcePubMed
dc.subjectCyclosporine
dc.subjectPterygium
dc.subjectFibroblasts
dc.subjectIn vitro
dc.titleIn vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución